Thermo Fisher Scientific Inc. Stock Performance
Thermo Fisher Scientific Inc. shares traded at $697, reflecting a daily decline of approximately 1.05%, per SID market data. Despite the session's weakness, the stock has demonstrated strong momentum across multiple timeframes, gaining 6.82% over the past month, 21.42% over three months, and 12.29% over the trailing twelve months, according to Massive/Polygon data. The stock currently trades well above both its 50-day moving average of $654.65 and its 200-day moving average of $543.42, indicating sustained bullish technical positioning. The 14-day relative strength index stands at 63.0, suggesting the stock remains in neutral-to-bullish territory without entering overbought conditions. Average daily trading volume registers at approximately 2.05 million shares, supporting a market capitalization of roughly $219.4 billion. Thermo Fisher's beta of 0.902 indicates slightly lower volatility than the broader market, consistent with its positioning within the healthcare sector.
Thermo Fisher Scientific Inc. Valuation Analysis
Thermo Fisher Scientific Inc. currently trades at a price-to-earnings ratio of 33.30, per SID market data, reflecting a premium valuation relative to the broader healthcare sector. The company's price-to-book ratio stands at 4.29, according to SEC filings, indicating that investors are paying a significant markup over the firm's book value per share. The PEG ratio registers at an elevated 577.17, suggesting that the current earnings multiple is not well supported by near-term earnings growth expectations. Thermo Fisher offers a modest dividend yield of approximately 0.29%, positioning it as a growth-oriented holding rather than an income investment. At a market capitalization of $219.4 billion, the company ranks among the largest healthcare companies globally. The valuation profile reflects the market's willingness to assign a premium to Thermo Fisher's diversified life sciences portfolio and its established leadership in analytical instruments and laboratory services.
Smart Money Activity for TMO
Thermo Fisher Scientific Inc. registers a smart money composite score of 46, signaling a neutral overall stance among sophisticated market participants, per SID market data. The institutional component scores a perfect 25 out of 25, indicating exceptionally strong institutional ownership and accumulation patterns, according to 13F institutional filings. In contrast, the insider trading component scores 9.5 out of 25, reflecting a cautious tone from company executives. SEC Form 4 filings reveal 20 insider transactions over the past 90 days, comprising 6 purchases and 14 sales, producing a buy-to-sell ratio that skews meaningfully toward net disposition. The dark pool activity component scores 8.5 out of 25, suggesting relatively muted off-exchange buying interest. Congressional trading activity registers at just 3.2 out of 25, indicating minimal disclosed legislative trading in TMO shares. The divergence between robust institutional conviction and insider selling activity presents a mixed signal for investors monitoring smart money flows in the stock.
Thermo Fisher Scientific Inc. Earnings Outlook
Thermo Fisher Scientific Inc. has delivered consecutive earnings beats across its three most recently reported quarters, according to company earnings reports. In the most recent quarter reported on October 21, the company posted earnings per share of $6.68, surpassing the consensus estimate of $6.40 by $0.28. The prior quarter saw EPS of $6.03 versus an estimate of $5.71, representing a positive surprise of $0.32, the largest beat in the reported sequence. The quarter ending April 23 produced EPS of $5.44 against expectations of $5.23, a $0.21 upside surprise. Analysts project EPS of $5.71 for the upcoming quarter scheduled for July 22, per analyst estimates. The sequential earnings trajectory from $5.44 to $6.03 to $6.68 demonstrates meaningful quarter-over-quarter growth. The consistent pattern of exceeding consensus estimates across all three reported periods highlights the company's operational execution and management's ability to deliver above-expectation financial results.
Wall Street Analyst Ratings for TMO
Wall Street consensus on Thermo Fisher Scientific Inc. remains uniformly bullish, with all five most recent analyst actions reiterating positive ratings, per Wall Street analyst reports. On October 30, Argus Research maintained its Buy rating on TMO shares. Following the company's October 21 earnings report, Citigroup reiterated a Buy rating on October 23, while both TD Cowen and Stifel maintained Buy ratings on October 22, according to SID consensus data. Baird also reaffirmed its Outperform rating on October 22. Notably, none of the five analysts adjusted their ratings from prior assessments, with each maintaining their previously established bullish stance. The clustering of reiterations immediately following the earnings release, where Thermo Fisher beat estimates by $0.28 per share, suggests that the strong quarterly results reinforced existing positive outlooks. The absence of any downgrades or neutral-rated coverage among recent analyst actions reflects broad confidence in the company's fundamental trajectory and competitive positioning within the life sciences industry.
